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Heat shock proteinWe recently reported that deletion of the stress-regulated nuclear protein 1 (Nupr1) protected against obesity-
associated metabolic alterations due to increased beta cell mass, but complete Nupr1 ablation was not advanta-
geous since it led to insulin resistance on a normal diet. The current study used Nupr1 haplodeﬁcient mice to in-
vestigate whether a partial reduction in Nupr1 expression conferred beneﬁcial effects on glucose homeostasis.
Islet number, morphology and area, assessed by immunoﬂuorescence and morphometric analyses, were not al-
tered in Nupr1 haplodeﬁcient mice under normal diet conditions and nor was beta cell BrdU incorporation. Glu-
cose and insulin tolerance tests indicated that there were no signiﬁcant changes in in vivo insulin secretion and
glucose clearance in Nupr1 haplodeﬁcient mice, and beta cell function in vitro was normal. However, reduced
Nupr1 expression decreased visceral fat deposition and signiﬁcantly increased insulin sensitivity in vivo. In con-
trast to wild type animals, high fat diet-fedNupr1 haplodeﬁcientmicewere not hyperinsulinaemic or glucose in-
tolerant, and their sustained insulin sensitivity was demonstrated by appropriate insulin-induced Akt
phosphorylation, as determined by Western blotting. At the molecular level, measurements of gene expression
levels and promoter activities identiﬁed Nupr1-dependent inhibition of heat shock factor-1-induced heat shock
protein 70 (Hsp70) expression as a mechanism through which Nupr1 regulates insulin sensitivity. We have
shown for the ﬁrst time that Nupr1 plays a central role in inhibiting Hsp70 expression in tissues regulating glu-
cose homeostasis, and reductions in Nupr1 expression could be used to protect against themetabolic defects as-
sociated with obesity-induced insulin resistance.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetes is one of the major causes of mortality worldwide with a
predicted incidence of 592million by 2035 according to the Sixth Inter-
national Diabetes Federation (IDF) Diabetes Atlas [1]. Hyperglycaemia is
the main feature of type 2 diabetes (T2D), which occurs as a conse-
quence of defective insulin action in peripheral tissues in combination
with impaired insulin secretion from islet beta cells [2,3]. It has become
evident that T2D development and obesity are linked to chronicismodel assessment-insulin re-
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authors of this work.inﬂammation and insulin resistance [4], resulting in decreased insulin-
stimulated Akt phosphorylation and consequent impaired GLUT4 glu-
cose transporter translocation to the plasma membrane in the muscle
and fat [5,6]. There is increasing evidence that the induction of heat
shock protein 70 (Hsp70), the major inducible molecular chaperone
[7,8], is linked to improved sensitivity in high-fat diet-fed mice [9]. In
contrast, Hsp70 is decreased in skeletal muscle of T2D patients, and its
reduced expression is correlated with the degree of insulin resistance
[10,11]. Furthermore, increased insulin-stimulated Akt phosphorylation
in liver cells has been observed in vitro following Hsp70 up-regulation
[12]. Thus, increasing Hsp70 expression might be helpful in treating
patients with insulin resistance to improve glucose homeostasis.
Heat shock proteins (Hsps) are a large family of proteins, many of
which are ubiquitously expressed in eukaryotic cells, whose expression
levels increase under stress conditions such as elevated temperature
and hypoxia [13–15]. When Hsps are up-regulated in cells they confer
protection against the stressful stimuli and allow maintenance of
cellular function [14,15]. Transcription of Hsps is regulated by the heat
shock transcription factors (Hsfs), and Hsf-1 is the main regulator of
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monomers dissociate from Hsps in the cytosol, are transported to the
nucleus where they form phosphorylated homotrimers and bind to
the hsp gene promoter, stimulating transcription. Direct binding of
Hsps to the Hsf-1 transactivation domain results in its inactivation and
subsequent reduction in Hsps expression [7,17].
We recently demonstrated that global deletion of Nupr1, a stress-
regulated protein, inmice promoted basal and glucose-stimulated insu-
lin secretion in vivo due to increased beta cell mass [18]. In addition, de-
letion of Nupr1 protected mice against obesity-associated perigonadal
fat mass accumulation, glucose intolerance and insulin resistance asso-
ciated with prolonged maintenance on a high fat diet. However, Nupr1
knockout mice fed a normal diet were insulin resistant, so complete ab-
lation of Nupr1 is not an ideal scenario for appropriate control of glucose
homeostasis. Our microarray analysis indicated that Nupr1 regulated
expression of Hspa1a, which codes for Hsp70 expression [18], so we
hypothesised that partial loss of Nupr1 could circumvent the potentially
deleterious effects seen with complete Nupr1 knockout on a normal
diet, while conferring beneﬁcial effects through increased expression
of Hsp70 and consequent improved insulin sensitivity. In the current
study we therefore characterised the metabolic phenotype of Nupr1
haplodeﬁcient C57BL/6 mice under normal conditions and when fed a
high fat diet to induce insulin resistance and glucose intolerance.
2. Materials and methods
2.1. Materials
Cell culture reagents were obtained from Sigma Aldrich (Poole, UK).
Molecular biology reagents were purchased from Invitrogen (Paisley,
UK) andPromega (Southampton, UK). SYBRGreen andBrdUproliferation
kits were from Roche (Burgess Hill, UK). Antibodies against insulin,
glucagon and somatostatin were from Dako UK (Ely, UK), and the
anti-phospho Akt(Ser473) antibody was supplied by New England
Biolabs (Hertfordshire, UK). Fluorescein isothiocyanate (FITC)- and
tetramethylrhodamine isothiocyanate (TRITC)-labelled secondary anti-
bodies were from Jackson Immunoresearch (Newmarket, UK).
Metafectene Pro was from Biontex Laboratories (Martinsried/Planegg,
Germany). Ultrasensitive mouse insulin ELISA kits were obtained from
Mercodia (Uppsala, Sweden).
2.2. Animals
The Nupr1 transgenic C57BL/6 mouse model was generated by
homologous recombination to delete exon 2 which encodes 60% of the
murine Nupr1 protein [19]. All procedures performed in this study
were approved by the local ethical committee and were in accordance
with the United Kingdom Home Ofﬁce standards. Mice were kept
under a light–dark cycle of 12 h and bred to generate wild-type and
Nupr1-haplodeﬁcient littermates. Mice were fed ad libitum with a
standard normal-fat diet (NFD; 4% fat), and for some experiments
they were fed a high-fat diet (HFD; 55% fat) for 16 weeks, starting at
5 weeks of age. All experiments were performed using age-matched
animals.
2.3. Metabolic studies
After i.p. administration of 2 g/kg glucose, glucose tolerance tests
were performed by quantiﬁcation of blood glucose concentrations
with a glucosemeter. Serum insulin levelswere determined using ultra-
sensitive ELISA kits. Insulin tolerance tests were performed following
i.p. administration of 0.75 U insulin per kg body weight. Weight gain
was recorded weekly until the day the mice were killed. Pancreases,
perigonadal fat pads and gastrocnemius muscles were retrieved on
the day the mice were killed, and were weighed.2.4. Immunohistochemistry and morphometric analysis
Pancreases were retrieved from wild-type and Nupr1-haplodeﬁcient
mice, ﬁxed in 4% paraformaldehyde, cut into 5 μm sections and morpho-
metric analyses were performed on every tenth section throughout each
pancreas. For quantiﬁcation of islet number and alpha, beta and delta cell
areas, sections were incubated with antibodies against glucagon,
insulin and somatostatin, and then with FITC- and TRITC-conjugated sec-
ondary antibodies. Islet size and the area of glucagon-, insulin- and
somatostatin-labelled cells on each section were quantiﬁed using ImageJ
software (ImageJ 1.45: http://rsbweb.nih.gov/ij/download.html).
Beta cell proliferationwas estimated following the administration of
1 mg/ml BrdU in drinking water to the mice for 7 days. Then, as
described above, ﬁxed pancreas sectionswere immunostained to detect
BrdU positive beta cells using anti-BrdU and anti-insulin antibodies.
2.5. Mouse islet isolation and dynamic insulin secretion
Islets were isolated by collagenase digestion of pancreases retrieved
from 3-month-old mice as described previously [20], and maintained in
culture for 24–48h in RPMI-1640medium(11mMglucose) supplement-
edwith 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. The
insulin secretory responses to 4 mM and 20 mM glucose, 100 nM
4β-phorbol myristate acetate (PMA) and 100 μM tolbutamide were
then assessed using a temperature-controlled perifusion device for
sample collection [21] and quantiﬁed by radioimmunoassay as previously
described [22].
2.6. Insulin-stimulated Akt phosphorylation
Insulin (5U per kg bodyweight) was administered i.p. to 14 h fasted
wild-type and Nupr1 haplodeﬁcient mice, which were culled 10 min
later. Samples of gastrocnemius muscle and perigonadal fat were
rapidly retrieved, frozen in liquid nitrogen and stored at−85 °C. Protein
immunoblot analysis [23] was performed using an anti-phospho Akt
antibody (1:1000 dilution) and normalised against tubulin expression
(1:2000 dilution of antibody) in the same samples.
2.7. Gene expression analyses
Messenger RNAswere extracted frompancreas, islets,MIN6 beta cells,
perigonadal fat and liver, puriﬁed and concentrated using Invitrogen
RNeasyminikits before being reverse-transcribed into cDNAs [18]. Quan-
titative PCR ampliﬁcations of Nupr1, Hsp1a and β-actin were performed
using the following conditions: denaturation at 95 °C for 10min, DNAam-
pliﬁcation using 35–40 cycles at 95 °C for 1 s, 60 °C for 10 s and 72 °C for
15 s. The primers used were: Nupr1 (F) 5′-gaagctgctgccaataccaacc-3′ and
(R) 5′-tagctctgcccgtctaccctc-3′; Hspa1a (F) 5′-gcactgccccgctgatgtga-3′ and
(R) 5′-gtggcccaggggagagtcca-3′; β-actin (F) 5′-atgaagtgtgacgttgacatccgt-3′
and (R) 5′-cctagaagcatttgcggtgcacgatg-3′.
2.8. Plasmids
Hsp70 promoter activities were assessed using −1512/0 mouse
Hspa1a and−1491/-1 mouse Hspa1b promoter-driven luciferase ex-
pression cloned into pGL2. The −1512/0 Hspa1a and −1491/-1
Hspa1b promoter sequences were produced by PCR ampliﬁcation
using a C57BL/6 mouse islet DNA library. The following primers were
used to introduce restriction sites for HindIII and NheI into Hspa1a:
(F) 5′-cacacgctagcgagtcagggtccaactatgtagctcaggc-3′, (R) 5′-cacacaagc
ttggcgccgcgctctgcttctggaaggctg-3′ and for SacI and HindIII into Hspa1b:
(F) 5′-cacacgagctcggggcagagaaggagaaaaggggaca-3′ and (R) 5′-cacacaa
gcttggcgccgcgctctgcttctggaaggct-3′. The PCR products were puriﬁed,
digested, inserted into the pGL2 luciferase reporter vector and se-
quenced. Experiments in which Nupr1 was overexpressed were
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Nupr1 gene as previously reported [18,24].
2.9. MIN6 beta cell transfection
For gene reporter assay studies, MIN6 beta cells were transiently
transfected using a Nucleofector II electroporation device as previously
described [23] and maintained in culture overnight at 37 °C in DMEM
(25 mM glucose) supplemented with 2 mM glutamine, 10% FBS,
100 units/ml penicillin and 100 μg/ml streptomycin. Promoter activity
levels were then determined by bioluminescence using luciferase
assay kits and normalised to β-galactosidase expression which was
co-transfected using pSV-β-Gal as described [18].
2.10. Data analysis
Numerical data are expressed as means ± SEM. The differences
between groups were assessed using Student's unpaired t-tests for
two group analyses, and one- or two-ways ANOVA followed by the
Tukey's HSD test formore than 3 groups or formultiple variable analysis
(genotype and diet), respectively. Differences between groups were
considered signiﬁcant at p b 0.05.
3. Results
3.1. Nupr1 haplodeﬁciency does not alter islet area or number
Quantitative RT-PCR analyses indicated that pancreaticNupr1mRNA
levelswere reduced by approximately 50% inNupr1 haplodeﬁcientmice
(Fig. 1A), conﬁrming the gene dosage reduction in expression withA B
C
Fig. 1. Nupr1 gene expression and beta cell proliferation. (A) Nupr1 gene expression levels in t
mice. (B) Representative immunographs of pancreas sections obtained from 3-month-old wild
(red) beta cells (green). (C) Number of BrdU-positive beta cells per islet and (D) number of B
black bars) and Nupr1 haplodeﬁcient (+/−, white bars) mice. Data are mean ± sem, n = 4 fodeletion of only one Nupr1 allele. Morphometric analyses of the endo-
crine pancreases of 3-month-old wild-type and Nupr1 haplodeﬁcient
mice indicated that the absence of one copy of the Nupr1 gene did not
signiﬁcantly affect islet area or number, nor were there any alterations
in the endocrine cell ratios (Table 1). Consistent with these results, no
signiﬁcant differences in the number of proliferating BrdU-positive
beta cells were observed between pancreases obtained from wild-type
and Nupr1 haplodeﬁcient mice that had been exposed to 1 mg/ml
BrdU in drinking water for 7 days (Fig. 1B–D).
3.2. Improved insulin sensitivity in Nupr1 haplodeﬁcient mice
Wehave previously reported that complete deletion ofNupr1 result-
ed in impaired insulin sensitivity without any signiﬁcant differences in
glucose tolerance, weight gain, or in gastrocnemius muscle and
perigonadal fat masses [18]. These metabolic and weight parameters
were therefore monitored in mice heterozygous for the Nupr1 gene
and compared to those obtained from their age-matched wild-type
littermates. No signiﬁcant differences in weight gain over 13 weeks
were observed between wild-type and Nupr1 haplodeﬁcient mice
(Fig. 2A and B). Similarly, the pancreas and gastrocnemius masses
were also very similar in 3-month-old wild-typemice and those lacking
one Nupr1 allele (Fig. 2C and D). We consistently observed that
perigonadal fat accumulation was reduced by 10–15% in Nupr1
haplodeﬁcient mice (Fig. 2E), although this reduction was not statisti-
cally signiﬁcant (p b 0.09).
To characterise the metabolic phenotype of Nupr1 haplodeﬁcient
mice, intraperitoneal glucose tolerance and insulin sensitivity tests
were performed, and serum insulin levels in response to glucose admin-
istration were also measured in 3-month-old animals after 16 h ofD
he pancreas of wild-type (+/+, black bars) and Nupr1 haplodeﬁcient (+/−, white bars)
-type (+/+) and Nupr1 haplodeﬁcient (+/−) mice showing proliferative BrdU-positive
rdU positive beta cells as a proportion of the total beta cell number in wild-type (+/+,
r both genotypes, *p b 0.05.
Table 1
Islet characteristics inwild-type andNupr1 haplodeﬁcientmice. Alpha, beta and delta cell areas and the beta/alpha, alpha/delta and beta/delta cell ratiosweremeasured by point-counting
morphometry from pancreas sections immunolabelled for insulin, glucagon and somatostatin inwild-type (Nupr1+/+) andNupr1 haplodeﬁcient (Nupr1+/−) mice. Data aremean± sem,
n = 4 for each genotype.
Islet area/pancreas
(% of total)
Islet number per mm2
pancreas
Mean cell areas per islet (μm2) Cell ratios per mm2 pancreas
Alpha
cell
Beta cell Delta
cell
Beta/alpha cell
ratio
Alpha/delta cell
ratio
Beta/delta cell
ratio
Nupr1+/+ 0.54 ± 0.09 0.47 ± 0.05 340 ± 71 10190 ± 1095 77 ± 19 24.4 ± 2.7 6.3 ± 1.3 138.7 ± 31.6
Nupr1+/- 0.72 ± 0.15 0.51 ± 0. 09 276 ± 51 8072 ± 1031 110 ± 40 28.4 ± 2.4 4.3 ± 0.8 125.8 ± 15.8
p-Value 0.08 0.63 0.56 0.21 0.49 0.3 0.24 0.7
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tion proﬁles (Fig. 3B) were not signiﬁcantly different in Nupr1
haplodeﬁcient mice, but these animals showed a signiﬁcant improve-
ment in insulin sensitivity 30 and 45 min after insulin (0.75 U/kg)
administration (Fig. 3C). Statistical comparisons of the areas under the
curves (insulin sensitivity curves (AUC): 1367.4 ± 63.2 (Nupr1+/+) vs.
1119.3 ± 80.8 (Nupr1+/−), p b 0.05) conﬁrmed these results.
In in vitro experiments in which isolated islets were perifused using
buffers supplemented with 4–20 mM glucose, 100 nM PMA or 100 μM
tolbutamide, although the ﬁrst phase of glucose-stimulated insulin re-
lease was slightly reduced in Nupr1 haplodeﬁcient islets, there were
no signiﬁcant differences between the insulin secretion proﬁles of
wild-type and Nupr1 haplodeﬁcient islets (Fig. 3D). Taken together,
our results indicate that the reduced Nupr1 expression in Nupr1
haplodeﬁcient mice improves insulin sensitivity without altering beta
cell mass or beta cell function and this enhanced insulin sensitivity is
not associated with improved glucose tolerance under standard diet
and environmental conditions of maintenance.Pancreas
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Fig. 2.Weight variables inwild-type andNupr1 haplodeﬁcientmice. (A–B) Total bodyweights o
to week 13. (C–E) Mean wild-type (+/+, black bars) and Nupr1 haplodeﬁcient (+/−, white b
expressed as gramper kg of bodyweight at week 13. Total bodyweights: n=66 (+/+), n= 69
and perigonadal fat pad indices: n = 15 (+/+), n = 20 (+/−).3.3. Reduced levels of Nupr1 protect against HFD-induced obesity and
obesity-associated metabolic defects
Because insulin sensitivitywas signiﬁcantly improved and therewas
a trend towards reduced perigonadal fat deposition in Nupr1
haplodeﬁcientmice fed normal chow,we further assessed the in vivo ef-
fect of reduced Nupr1 expression on the weight and metabolic parame-
ters following the administration of a high- (55%) fat diet (HFD) for
16 weeks. As expected, prolonged maintenance of wild-type mice on
the HFD resulted in impaired glucose tolerance that was characterised
by signiﬁcant elevation in fasting hyperglycaemia and serum insulin
compared to wild-type mice fed standard chow containing 4% fat
(Table 2). In contrast, HFD-fed Nupr1 haplodeﬁcient animals did not
show signiﬁcant increases in circulating glucose or insulin concentra-
tions, and Nupr1 reduction also partially protected against HFD-
induced body weight gain (Table 2). In a similar manner, there was a
50% lower perigonadal fat deposition in Nupr1+/−mice over 16 weeks
than in age-matched HFD-fed wild-type mice (Table 2). Moreover,Perigonadal fatemius
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type mice 15, 30 and 45 min-post insulin administration, HFD-fed
Nupr1 haplodeﬁcient animals showed similar insulin-induced glucose
uptake curves to those fed a NFD (Fig. 4A), suggesting that reduced
levels of Nupr1 also confer a protection against obesity-induced insulin
resistance. Improved insulin sensitivity of Nupr1 haplodeﬁcient mice
was conﬁrmed by phospho-Akt immunoblot analysis, which indicated
that Nupr1+/− mice did not show reduced insulin-induced Akt
phosphorylation in gastrocnemius muscle (Fig. 4D) and perigonadal
fat (Fig. 4E) after maintenance on a HFD for 16 weeks, whereas in
HFD-fed wild-type mice Akt phosphorylation was reduced by approxi-
mately 50%. Thus, not surprisingly, serum insulin levels were increased
in wild-type animals fed a HFD, but this did not occur in mice heterozy-
gous for Nupr1 (Table 2 and Fig. 4B). As a result, glucose tolerance was
signiﬁcantly impaired in HFD-fed wild-type mice after 16 weeks of
treatment, but it was not altered in mice heterozygous for Nupr1
(Fig. 4C), and these observations were conﬁrmed by quantiﬁcation ofTable 2
Metabolic variables fromNFD- and HFD-fedwild-type and Nupr1 haplodeﬁcient mice. Body
and perigonadal fatweight gain, fasting blood glucose and seruminsulin levels were mea-
sured in NFD- and HFD-fed wild-type (Nupr1+/−) and Nupr1 haplodeﬁcient (Nupr1+/−)
mice after 16 weeks. Insulin resistance was assessed using the homeostatic model assess-
ment HOMA-IR. Data are mean ± sem, n = 3 for each genotype and diet.
Nupr1+/+ Nupr1+/−
NFD HFD NFD HFD
Body weight gain (g) 2.5 ± 0.95 119.5 ± 1.7⁎ 9.3 ± 1.3 14.5 ± 3.1
Perigonadal fat (g/kg
body weight)
9.8 ± 0.7 33.4 ± 5.3⁎ 8.9 ± 0.9 20.6 ± 2.5
Blood glucose (mM) 5.9 ± 0.53 1 ± 0.44⁎ 6.0 ± 0.49 6.9 ± 0.19
Serum insulin (ng/mL) 0.6 ± 0.03 1.2 ± 0.16⁎ 0.5 ± 0.09 0.4 ± 0.02⁎⁎
HOMA-IR 3.5 ± 0.06 11.2 ± 1.53⁎ 3.4 ± 0.36 2.7 ± 0.46⁎⁎
⁎ p b 0.05 relative to NFD wild-type mice.
⁎⁎ p b 0.05 relative to HFD-fed wild-type mice.area under the curve measurements (Fig. 4F), which indicated that
glucose tolerance was signiﬁcantly improved in the Nupr1+/− mice
after 16 weeks on a HFD compared to age-matched wild-type mice on
the HFD. Insulin resistance was assessed using the homeostasis model
assessment, HOMA-IR, and this further conﬁrmed that reduced Nupr1
expression improved insulin sensitivity in HFD-fed animals while it
was reduced by more than 3-fold in obese wild-type mice (Table 2).
The improved glucose handling was not increased related to beta cell
mass expansion since immunohistochemical analyses of pancreases re-
trieved fromHFD-fedwild-type andNupr1 haplodeﬁcientmice that had
been administered 1 mg/ml BrdU for 7 days prior to sacriﬁce indicated
that there were no signiﬁcant differences in beta cell number between
genotypes (BrdU-positive beta cells per islet, Nupr1+/− mice: 78.5 ±
36.6% of wild-type; BrdU-positive cells per total beta cells, Nupr+/−
mice: 81.8 ± 48.5% of wild-type, p N 0.2, n = 4 for each genotype).
3.4. Nupr1 controls Hsp70 promoter activity and mRNA expression
It is well-established that reductions in body mass index are associ-
ated with improved insulin sensitivity, and increased levels of visceral
fat-derived pro-inﬂammatory adipokines involved in insulin resistance
occur in obesity [25]. It is therefore likely that the protection against ex-
cessive weight gain and perigonadal fat deposition shown by HFD-fed
Nupr1+/− mice protected them against metabolic derangement. We
sought to identify a Nupr1-dependent mechanism of improved glucose
handling in these mice, and focused on heat shock protein 70 (Hsp70)
since this protein is known to reduce visceral adiposity and insulin
resistance in mice and humans [9,26], and our microarray analysis
indicated that complete ablation of Nupr1 affects expression of Hspa1a
(also known as Hsp70-1 or Hsp72), which encodes Hsp70 [18]. Thus,
given our demonstration that insulin sensitivity is signiﬁcantly
improved in Nupr1 haplodeﬁcient mice, we monitored the expression
of Hspa1a mRNA in insulin-sensitive tissues and islets when Nupr1
expression was reduced. Quantitative RT-PCR indicated that Hspa1a
AB
C
F
D E
Fig. 4.Metabolic variables during a high fat diet challenge. Determination of NFD- (solid lines and black bars) and HFD-fed (dashed lines and white bars) wild-type (+/+) and Nupr1
haplodeﬁcient mice (+/−) glucose (A, C) and serum insulin (B) levels after 16 weeks of treatment. (A) Insulin sensitivity tests were performed after administration of 0.75 U/kg insulin.
(B) Serum insulin levels were determined at fast and after an i.p glucose challenge. (C) Glucose tolerance tests were carried out following i.p. administration of glucose. (D, E) Akt phos-
phorylation was determined in gastrocnemius muscle (D) or perigonadal fat (E) 10 min after i.p. insulin injection and compared with tubulin expression in the same samples (upper
panels). Densitometric data of immunoreactive protein densities are shown in the lower panels. (F) Areas under the curves (AUC) were calculated from the glucose tolerance curves in
panel C. Data are mean ± sem of repeated measures, n = 3 for each genotype and diet condition, (*, $, #) p b 0.05 and (**, $$, ##) p b 0.01 relative to NFD-fed wild-type mice (*, **),
NFD-fed heterozygous mice ($, $$) and HFD-fed wild-type mice (#, ##), respectively.
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Nupr1+/− mice fed on standard chow (Fig. 5, black bars), consistent
with the improved insulin sensitivity of these mice. Moreover, while
both wild-type and Nupr1+/− mice maintained on a HFD showed
signiﬁcant reductions in Hspa1a mRNA in fat and liver, the levels in
Nupr1 haplodeﬁcient HFD mice were not signiﬁcantly different from
those observed in wild-typemice on the NFD diet (Fig. 5). Furthermore,A B
Fig. 5. IncreasedHspa1a expression inNupr1 haplodeﬁcient tissues. Quantitative RT-PCR ampliﬁ
(C) islets retrieved fromNFD- (black bars) andHFD-fed (white bars)wild-type (+/+) andNupr
genotype and diet, (#) p b 0.05 and (**, $$, ##) p b 0.01 relative to NFD-fed wild-type mice (**),islets retrieved from Nupr1+/−mice did not show the HFD-induced re-
duction in Hspa1amRNA levels that occurred in wild-type mice on the
HFD (Fig. 5). The reasons for this are not entirely clear, but the data
are consistent with improved Hspa1amRNA levels under conditions of
metabolic stress. Overall, Nupr1 haplodeﬁciency was associated with
signiﬁcantly increasedHspa1amRNA expression in all tissues examined
in both NFD and HFD conditions.C
cation data showing gene expression levels ofHspa1a in (A) perigonadal fat, (B) liver, and
1haplodeﬁcient (+/−)mice. Values aremean± semof repeatedmeasures, n=3 for each
NFD-fed heterozygous mice ($$) and HFD-fed wild-type mice (#, ##), respectively.
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pression mouse MIN6 beta cells were transiently co-transfected either
with the promoterless pGL2/Luc plasmid (pGL2) or Hspa1a promoter-
driven pGL2/Luc vectors (Hspa1a/pr), and pcDNA3.1/NUPR1 and/or
pcDNA3.1/Hsf-1 coding for the full-length forms of the human NUPR1
and mouse Hsf-1 proteins, respectively. As expected, the basal Hspa1a
promoter activity was low under standard culture conditions and a
4-fold stimulation was observed following Hsf-1 overproduction
(Fig. 6A). Overexpression of NUPR1 did not signiﬁcantly alter the
Hspa1a promoter activity in the absence of Hsf-1-induced stimulation,
but it signiﬁcantly repressed Hspa1a transactivation by 38± 6% follow-
ing Hsf-1 overproduction (Fig. 6A). Similar results were obtained in
gene reporter assays in which the luciferase activity was driven by the
−1491/-1 bp mouse Hspa1b promoter (Fig. 6B) which drives the
expression of a second Hsp70 isoform known as Hsp70-2. In these
experiments NUPR1 overexpression did not alter basal Hspa1b promot-
er activity, but it signiﬁcantly reduced (by 47± 5%) activity induced by
Hsf-1 (Fig. 6B).
4. Discussion
Wepreviously reported that the stress-activated protein NUPR1 acts
as a tonic endogenous inhibitor of beta cell proliferation and expansion
viamolecular mechanisms involving repression of cell-cycle regulatory
genes such as TCF19 and CCNA2 [18]. An increased beta cell mass in
Nupr1 null mice conferred protection against high fat diet (HFD)-in-
duced obesity, but on normal diets deletion of Nupr1 was associated
with insulin resistance.
This study used Nupr1 haplodeﬁcient mice to test whether reducing
rather than ablating Nupr1 expression could be beneﬁcial for mainte-
nance of glucose homeostasis and we now conﬁrm that Nupr1 is indeed
a potential molecular target for future drug-based therapies to treat
obesity and obesity-associated metabolic defects. Thus, as we previously
reported for Nupr1 knockout mice, halving Nupr1 expression levels was
sufﬁcient to protect mice from themetabolic stresses induced bymainte-
nance on a 55% fat diet for 16 weeks. We have found that high fat fed
Nupr1 haplodeﬁcient mice were normoglycaemic, glucose tolerant and
sensitive to insulin, while wild type mice showed the typical metabolic
derangements associated with prolonged high fat feeding. The improve-
ments in glucose handling in Nupr1+/−mice were not secondary to in-
creased beta cell mass, but to direct improvements in insulin sensitivity
that was associated with lower body weight gain and reduced visceralA
Fig. 6.Nupr1down-regulatesHspa1a andHspa1b promoter activities. (A)Hspa1a and (B)Hspa1
the (co)transfection of thepromoterless pGL2/luciferase plasmid (pGL2), the−1512/0Hspa1a (H
andpcDNA3.1 coding for the full lengthhumanNUPR1 ormouseHsf-1 proteins. Data aremean±
stimulated Hspa1a or Hspa1b promoter activities.fat accumulation. In addition, perigonadal fat mass accumulation was
also reduced and insulin sensitivity increased inNupr1 haplodeﬁcient an-
imals fed a normal diet, in contrast to the impaired insulin sensitivity that
we had previously seen in Nupr1 knockout mice maintained on a normal
diet [18].
One of the key signal transduction cascades downstream of insulin
binding to its receptor is through phosphorylation and activation of
the serine/threonine kinase Akt, which is responsible for GLUT4 translo-
cation to the plasmamembrane to allow glucose uptake into adipocytes
and myocytes [27]. It has been reported that Hsps induction via heat
shock and mild electrical stimulation can ameliorate insulin resistance
by enhancing insulin signalling in the liver, where increased Akt phos-
phorylation was observed [12,26]. Here, we demonstrate that Nupr1
haplodeﬁcientmice show insulin-induced Akt phosphorylation inmus-
cle and perigonadal fat even when fed a high fat diet, while wild-type
mice exhibited insulin resistance, as expected, on this diet. Our observa-
tions of increased expression of Hspa1a, a mRNA encoding a heat shock
protein 70 (HSP70) familymember, in perigonadal fat, liver and islets of
insulin-sensitive Nupr1 haplodeﬁcient mice, are consistent with Hsp70
playing a role in the increased insulin sensitivity of these mice.
Although Hsp70 protein levels were not quantiﬁed in the current
study, there is a close correlation between Hspa1a mRNA levels and
Hsp70 expression [28–30]. In addition, when Hsp70 has completed its
functional effects it undergoes ubiquitin-dependent degradation to
decrease its levels [30] or it may show increased stability when further
cellular protection is required [31].
Heat shock proteins function as chaperone molecules and can
provide protection against obesity-associated metabolic dysfunction
[9]. For example,HSPA1A expression is reduced inmuscle biopsies of di-
abetic patients [10,11] and impaired induction of its transactivating fac-
tor HSF-1 in hyperglycaemic diabetic monkeys has been reported [32].
Consistent with these observations, oral administration of chemical
chaperones to obese and type 2 diabetic animals can restore glucose ho-
meostasis and insulin sensitivity [33] and Hsp70 overexpression in high
fat fedmice is reported to prevent the development of insulin resistance
by inhibiting JNK-mediated inﬂammation [9]. Strategies directed at in-
creasing heat shock protein expression have been proposed as a
means of improving insulin sensitivity [26,34–36] and it has been
reported that mean body weight, fasting plasma glucose and glycated
haemoglobin levels of individuals with T2D were signiﬁcantly
decreased following a three-week heat shock treatment [34]. Further
support for a role for heat shock proteins in counteracting insulinB
b promoter activitieswere determined inMIN6 beta cells by gene reporter assays following
spa1a/pr) or−1491/-1Hspa1b (Hspa1B/pr) promoter-driven luciferase expression vectors,
sem, n=3, *p b 0.05 relative toHspa1a/pr (A) orHspa1b/pr (B), #p b 0.05 relative toHsf-1-
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and glucose utilisation following the administration of BGP-15, a
co-inducer of heat shock proteins, to non-diabetic patientswith impaired
glucose tolerance [35].
The improved insulin sensitivity and increased Hspa1a mRNA ex-
pression that we observed in Nupr1+/− mice suggest that deletion of
one Nupr1 allele permitted up-regulation of Hsp70 in insulin-sensitive
tissues as a mechanism of protecting against diet-induced insulin resis-
tance.We therefore investigatedwhether Nupr1 acts as a tonic inhibitor
of Hsp70 expression using gene reporter assays and found that Nupr1
overexpression signiﬁcantly repressed Hsf-1-induced Hspa1a promoter
transactivation, and similar data were obtained when we measured
promoter activity of the other Hsp70 family member, Hspa1b. It has
previously been reported that Nupr1 can regulate transactivation of
transcription factors through binding to protein partners including
p300 [37]. It is possible that Nupr1 inhibits Hsf-1-mediated induction
of Hspa1a/b through interaction with p300 since it is known that this
cofactor plays a role in Hsp70 transcription [38,39]. Thus, our observa-
tions are consistent with a molecular model in which Nupr1 negatively
regulates HSF-1 DNA binding activity and Hsp70 gene transactivation,
and they are likely to be important in explaining the improvedmetabol-
ic status of Nupr1+/−mice fed on a high fat diet.
In summary, our study demonstrates for the ﬁrst time that the
stress-regulated Nupr1 protein plays a central role in the regulation of
mRNA encoding Hsp70 expression in tissues involved in the control of
glucose homeostasis, and that reduction in Nupr1 expression and/or ac-
tivity could represent a novel therapeutic approach to reduce obesity-
associated adipose tissue accumulation and improve insulin sensitivity
and glucose tolerance.
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